Taylor & Francis Group
Browse
1/1
11 files

Hypoxia-induced autophagy drives colorectal cancer initiation and progression by activating the PRKC/PKC-EZR (ezrin) pathway

dataset
posted on 2019-11-28, 04:37 authored by Komal Qureshi-Baig, Diana Kuhn, Elodie Viry, Vitaly I. Pozdeev, Martine Schmitz, Fabien Rodriguez, Pit Ullmann, Eric Koncina, Martin Nurmik, Sonia Frasquilho, Petr V. Nazarov, Nikolaus Zuegel, Marc Boulmont, Yervand Karapetyan, Laurent Antunes, Daniel Val, Michel Mittelbronn, Bassam Janji, Serge Haan, Elisabeth Letellier

In solid tumors, cancer stem cells (CSCs) or tumor-initiating cells (TICs) are often found in hypoxic niches. Nevertheless, the influence of hypoxia on TICs is poorly understood. Using previously established, TIC-enrichedpatient-derived colorectal cancer (CRC) cultures, we show that hypoxia increases the self-renewal capacity of TICs while inducing proliferation arrest in their more differentiated counterpart cultures. Gene expression data revealed macroautophagy/autophagy as one of the major pathways induced by hypoxia in TICs. Interestingly, hypoxia-induced autophagy was found to induce phosphorylation of EZR (ezrin) at Thr567 residue, which could be reversed by knocking down ATG5, BNIP3, BNIP3L, or BECN1. Furthermore, we identified PRKCA/PKCα as a potential kinase involved in hypoxia-induced autophagy-mediated TIC self-renewal. Genetic targeting of autophagy or pharmacological inhibition of PRKC/PKC and EZR resulted in decreased tumor-initiating potential of TICs. In addition, we observed significantly reduced in vivo tumor initiation and growth after a stable knockdown of ATG5. Analysis of human CRC samples showed that p-EZR is often present in TICs located in the hypoxic and autophagic regions of the tumor. Altogether, our results establish the hypoxia-autophagy-PKC-EZR signaling axis as a novel regulatory mechanism of TIC self-renewal and CRC progression. Autophagy inhibition might thus represent a promising therapeutic strategy for cancer patients.

ATG: autophagy related; BECN1: beclin 1; BNIP3: BCL2 interacting protein 3; BNIP3L: BCL2 interacting protein 3 like; CQ: chloroquine; CSC: cancer stem cells; CRC: colorectal cancer; HIF1A/HIF-1α: hypoxia inducible factor 1 subunit alpha; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; PRKC/PKC: protein kinase C; SQSTM1/p62: sequestosome 1; TICs: tumor-initiating cells.

Funding

This project was supported by the TELEVIE (28504270, R-AGR-3140) and Fondation Cancer (grant F1R-LSC-PAU-13HY2C) and Janssen Cilag. Dr. Komal Qureshi-Baig, Dr. Pit Ullmann and Martin Nurmik are supported by the Fonds National de la Recherche (FNR) (under the AFR grant scheme and PRIDE scheme) and by the Fondation du Pélican de Mie and Pierre Hippert-Faber under the aegis of the Fondation de Luxembourg. EV is supported by a TELEVIE grant (7456517, R-AGR-3377). EL is supported by a CORE (C16/BM/11282028) and a POC grant (PoC18/12554295). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

History